A double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety, pharmacokinetics and efficacy of CRN00808 in patients with acromegaly that are responders to octreotide LAR or lanreotide depot (ACROBAT Evolve)
Phase of Trial: Phase II
Latest Information Update: 05 Nov 2019
Price : $35 *
At a glance
- Drugs CRN-00808 (Primary)
- Indications Acromegaly
- Focus Therapeutic Use
- Acronyms ACROBAT EVOLVE
- Sponsors Crinetics Pharmaceuticals
- 19 Mar 2019 According to a Crinetics Pharmaceuticals media release, the first patient has been dosed in this trial.
- 08 Jan 2019 New source identified and integrated (ClinicalTrials.gov Identifier:NCT03792555)
- 01 Jan 2019 Planned primary completion date changed to 1 Jun 2020.